Trovagene to Present New Data from Onvansertib Phase 2 Study in Metastatic Castration-Resistant Prostate Cancer at Asia-Pacific Prostate Cancer Conference

SAN DIEGO, Aug. 15, 2019 /PRNewswire/ — Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company, developing drugs that target cell division (mitosis), for the treatment of various cancers, including prostate, colorectal and leukemia, today announced that new clinical data from its Phase 2 trial of onvansertib, in combination with Zytiga® (abiraterone acetate)/prednisone, in metastatic Castration-Resistant Prostate Cancer (mCRPC), will be presented as an oral poster at the 20th Asia-Pacific Prostate Cancer Conference, which will be held August 23-26 in Melbourne, Australia.

The data will be presented in an oral, moderated poster session on Saturday, August 24, 2019 at 1:00 pm (AEDT)

Details of the Trovagene Poster Presentation are as follows:

Title: A Phase 2 Study of the Combination of PLK1 Inhibitor, Onvansertib, with Abiraterone and Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Abstract Number: 1044

Moderated Poster Session: Clinical Urology

Location: Goldfields Exhibition

About Trovagene, Inc.

Trovagene is a clinical-stage, oncology therapeutics company, taking a precision cancer medicine approach to develop drugs that target mitosis (cell division) to treat various types of cancer, including leukemias, lymphomas and solid tumors. Trovagene has intellectual property and proprietary technology that enables the Company to analyze circulating tumor DNA (ctDNA) and clinically actionable markers to identify patients most likely to respond to specific cancer therapies. Trovagene plans to continue to vertically integrate its tumor genomics technology with the development of targeted cancer therapeutics.  For more information, please visit https://www.trovageneoncology.com.

Trovagene Contact:
Vicki Kelemen
VP, Clinical Development and Investor Relations
858-952-7652
vkelemen@trovagene.com 

View original content to download multimedia:http://www.prnewswire.com/news-releases/trovagene-to-present-new-data-from-onvansertib-phase-2-study-in-metastatic-castration-resistant-prostate-cancer-at-asia-pacific-prostate-cancer-conference-300901999.html

SOURCE Trovagene, Inc.

Staff

Recent Posts

Daily Fit Notes Rolls Out Affordable Fitness Solutions for the Modern Lifestyle

Daily Fit Notes, founded by Justin Brey in New York, launches a text-based subscription fitness…

2 days ago

WillowWood Rebrand by DD.NYC Wins Gold Anthem Award for Product and Innovation in 2024 Rebrand

MT. STERLING, Ohio, Dec. 20, 2024 /PRNewswire/ -- WillowWood, a global leader in prosthetic solutions,…

2 days ago

Quantum Biopharma Announces Closing of Second Tranche

TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"…

2 days ago

Glow Lifetech Announces Completion of Final Payment under Swiss Pharma Share Exchange Agreement and Debt Settlement

Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink:…

2 days ago